Bruton tyrosine kinase (BTK) enzyme inhibitors used to treat B-cell cancers, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma, also produce resistance by causing mutations in the protein. Now, a study on the BTK degrader NX-2127 showed the compound could be effective in eliminating BTK regardless of its mutations. Read More
Stroke is the main neurologic cause of global morbidity and mortality with a global prevalence of more than 100 million last year. Under neuropathological conditions such as excitotoxicity associated with stroke, the pro-glycolytic enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) enhances glucose consumption which leads to redox stress and apoptotic neuronal death. Read More
Anima Biotech Inc. has released promising preclinical data on its new candidate, which has potential for treating idiopathic pulmonary fibrosis (IPF). Read More
Agonists of the glucagon-like peptide-1 receptor (GLP-1RAs) have emerged as effective treatments for obesity, but have a negative impact on lean mass during weight loss. Read More
Tetra Pharm Technologies ApS has announced it is advancing its cannabinoid CB1 receptor antagonist, TPT-0701, into preclinical testing for appetite suppression. Read More
The University of Texas MD Anderson Cancer Center and C-Biomex Ltd. have announced a strategic research collaboration agreement to co-develop CBT-001, a radioligand targeting the CA9 cancer biomarker. Read More
Vandria SA has been awarded two grants totaling €3.8M (US$4.1M) from Innosuisse and Eurostars to support its two lead drug candidates addressing CNS and muscle diseases, respectively. Read More
A Biogen Inc. patent describes new non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of stroke, psoriasis, arthritis, pain, silicosis, alopecia, inflammatory disorders and autoimmune diseases. Read More
Bleeding of unknown cause (BUC) is a diagnosis of exclusion, and it is common for these patients to have congenital platelet function disorders. Whole-exome sequencing may help reach a more accurate diagnosis in these cases. Read More
The bromodomain and extraterminal domain (BET) family of proteins are involved in cell cycle regulation and for this reason are considered therapeutic targets in cancer therapeutics. Read More
It has been previously demonstrated that noise exposure leads to activation of the mitogen-activated protein kinase (MAPK) pathway, and that inhibition of this pathway protects from hearing loss. Tizaterkib (formerly AZD-0364) is a novel, highly selective, orally bioavailable ERK1/2 inhibitor that is currently in early clinical development for the treatment of cancer. In recent work, investigators from Creighton University aimed to assess the potential of tizaterkib for the treatment of noise-induced hearing loss (NIHL). Read More
Work at Nextgen Bioscience Co. Ltd. has led to the development of purine derivatives acting as hypoxia-inducible factor 1α (HIF-1α) inhibitors. Read More
Myrobalan Therapeutics Inc. has been awarded a $400,000 grant from the ALS Association to support the advancement of its colony-stimulating factor 1 receptor (CSF-1R) inhibitor for the treatment of amyotrophic lateral sclerosis (ALS). Read More
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has patented proteolysis targeting chimera (PROTAC) compounds comprising cereblon (CRBN) ligands covalently bonded to a Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1)-targeting moiety through a linker. Read More
